Avalo Therapeutics (NASDAQ:AVTX) Releases Earnings Results, Beats Expectations By $1.17 EPS

Avalo Therapeutics (NASDAQ:AVTX) announced its quarterly earnings data on Monday. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $1.17, FiscalAI reports. The company had revenue of $0.06 million during the quarter.

Avalo Therapeutics Stock Up 8.6%

Avalo Therapeutics stock traded up $1.16 during trading on Wednesday, hitting $14.61. The stock had a trading volume of 402,031 shares, compared to its average volume of 520,416. The stock’s 50 day moving average is $15.57 and its two-hundred day moving average is $15.78. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72. The stock has a market cap of $270.43 million, a price-to-earnings ratio of -2.55 and a beta of 0.84.

Analysts Set New Price Targets

Several equities analysts have issued reports on AVTX shares. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. BTIG Research reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Guggenheim began coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 target price for the company. Finally, HC Wainwright raised their price target on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $42.25.

Insider Transactions at Avalo Therapeutics

In other news, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares in the company, valued at $58,495.30. The trade was a 87.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.25% of the stock is owned by insiders.

Institutional Trading of Avalo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Boothbay Fund Management LLC bought a new position in Avalo Therapeutics in the second quarter worth about $56,000. Dimensional Fund Advisors LP purchased a new position in shares of Avalo Therapeutics during the 3rd quarter worth approximately $143,000. Jump Financial LLC bought a new position in shares of Avalo Therapeutics in the 4th quarter worth approximately $238,000. Persistent Asset Partners Ltd purchased a new position in Avalo Therapeutics during the fourth quarter valued at $274,000. Finally, Hudson Bay Capital Management LP bought a new stake in Avalo Therapeutics during the fourth quarter worth about $305,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.